245 related articles for article (PubMed ID: 20401670)
21. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
22. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
Da Fonseca CO; Masini M; Futuro D; Caetano R; Gattass CR; Quirico-Santos T
Surg Neurol; 2006 Dec; 66(6):611-5. PubMed ID: 17145324
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
26. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
27. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
28. High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Marinelli A; Lamberti G; Cerbone L; Cordua N; Buonerba C; Peluso G; Di Lorenzo G; De Placido S
Medicine (Baltimore); 2018 Jul; 97(27):e11254. PubMed ID: 29979390
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
30. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
31. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
Bloch O; Crane CA; Fuks Y; Kaur R; Aghi MK; Berger MS; Butowski NA; Chang SM; Clarke JL; McDermott MW; Prados MD; Sloan AE; Bruce JN; Parsa AT
Neuro Oncol; 2014 Jan; 16(2):274-9. PubMed ID: 24335700
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
[TBL] [Abstract][Full Text] [Related]
33. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma.
Santos JG; Da Cruz WMS; Schönthal AH; Salazar MD; Fontes CAP; Quirico-Santos T; Da Fonseca CO
Oncol Lett; 2018 Jan; 15(1):1263-1270. PubMed ID: 29391903
[TBL] [Abstract][Full Text] [Related]
35. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
36. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.
Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH
J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508
[TBL] [Abstract][Full Text] [Related]
37. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
Silvani A; De Simone I; Fregoni V; Biagioli E; Marchioni E; Caroli M; Salmaggi A; Pace A; Torri V; Gaviani P; Quaquarini E; Simonetti G; Rulli E; D'Incalci M;
J Neurooncol; 2019 May; 142(3):455-462. PubMed ID: 30726533
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Kunwar S; Chang S; Westphal M; Vogelbaum M; Sampson J; Barnett G; Shaffrey M; Ram Z; Piepmeier J; Prados M; Croteau D; Pedain C; Leland P; Husain SR; Joshi BH; Puri RK;
Neuro Oncol; 2010 Aug; 12(8):871-81. PubMed ID: 20511192
[TBL] [Abstract][Full Text] [Related]
40. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
